Research progress on clinical monitoring of monoclonal antibody drugs
10.3760/cma.j.cn114015-20210823-00920
- VernacularTitle:单克隆抗体药物临床监测研究进展
- Author:
Likun DING
1
;
Tingting FAN
1
;
Meiyou LIU
1
;
Yue GUAN
1
;
Jingwen WANG
1
;
Aidong WEN
1
Author Information
1. 空军军医大学第一附属医院药剂科，西安 710032
- Publication Type:Journal Article
- Keywords:
Biopharmaceutics;
Drug monitoring;
Drug-related side effects and adverse reactions;
Safety;
Monoclonal antibody drugs
- From:
Adverse Drug Reactions Journal
2022;24(9):484-489
- CountryChina
- Language:Chinese
-
Abstract:
Monoclonal antibody (mAb) drugs belong to protein drugs, which are characterized by high relative molecular weight, strong polarity, and limited transmembrane. Their pharmacokinetics have certain particularity and complexity, and problems such as large individual differences in therapeutic effects, diverse biological effects, and loss of therapeutic response exist in clinical application. The blood concentration of mAb drugs is affected by many factors including the number of receptors at the target site, the level of anti-drug antibody, and the interaction between drugs. Early monitoring is helpful to timely adjust the dose of mAb drugs, improve the efficacy, and avoid or reduce the occurrence of adverse reactions. Clinical monitoring should be actively carried out to improve the level of rational use of mAb drugs and the ability of early warning of adverse reactions, so as to reduce the drug-induced injury in patients.
